Search Results 711-720 of 18068 for Alopecia

1. Laser resurfacing - Doctors & Departments - Mayo Clinic

   ... Alopecia areata, Oral ulcerative condition, Facial volume loss, Vulvar disorder. Show more areas of focus for Alison J. Bruce, M.B., Ch.B.

2. A Study to Evaluate Genetic Testing in Guiding Treatment for Patients with Brain Metastases - Mayo Clinic

   ... alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and ...

3. Safusidenib Phase 2 Study In IDH1 Mutant Glioma - Mayo Clinic

   conditions such as alopecia, temozolomide-induced lymphopenia and irreversible changes associated with radiation therapy). 12. Female patients who engage in ...

4. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

   Recovery to ≤ Grade 1 or baseline of any non-hematological toxicities due to previous therapy, except alopecia and peripheral neuropathy. Females of ...

5. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

   ... alopecia and peripheral sensory neuropathy. - Subjects of childbearing potential agree to use two forms of medically approved contraception while taking the ...

6. Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

   Resolution of all acute toxic effects of prior induction anti-HER2-based chemotherapy regimen to NCI CTCAE version 4.0 Grade ≤1 (except alopecia or other ...

7. A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma - Mayo Clinic

   Patients with Grade 2 neuropathy or Grade 2 alopecia are eligible. Active idiopathic thrombocytopenic purpura. Active central nervous system (CNS) ...

8. A Study Of AL101 In Patients with Adenoid Cystic Carcinoma Bearing Activating Notch Mutations - Mayo Clinic

   0) ≤ Grade 1, except for sensory neuropathy with resolution to ≤ Grade 2 and alopecia. Male and/or Female: Contraceptive use by men or women should be ...

9. A Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer - Mayo Clinic

   Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, ...

10. A Study to Analyze CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma - Mayo Clinic

    0], with the exception of persistent alopecia, hypothyroidism, and adrenal insufficiency) due to prior treatment. NOTE: Subjects previously treated with a ...